Given the rise in DAVE shares, we analyze its current position to determine whether investors should ride the rally or avoid it.

UiPath's recent Peak acquisition is likely to drive renewed growth opportunity. Read why we are reiterating our Buy rating ...

UiPath has been named a Leader in Intelligent Document Processing in the Everest Group IDP Products PEAK Matrix® Assessment ...

Visa also continually rolls out new products that deliver benefits to customers, vendors, and merchants. Earlier in April, ...

Microsoft and UiPath have announced a partnership in enterprise automation with the launch of integration between Microsoft Copilot Studio and UiPath Studio.

Mizuho lowered the firm’s price target on UiPath (PATH) to $11 from $12 and keeps a Neutral rating on the shares as part of a Q1 preview for ...

(Nasdaq:CFLT), the data streaming pioneer, today announced the promotion of Ryan Mac Ban to Chief Revenue Officer (CRO). In this expanded role, Ryan will lead the global field strategy, bringing ...

Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses.

UiPath (PATH) appears an attractive pick given a noticeable improvement in the company's earnings outlook. The stock has been ...

Learn more about whether UiPath Inc. or Qualys, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Asana, Inc. or UiPath Inc. is a better investment based on AAII's A+ Investor grades, which compare ...

UiPath shares rise on launch of generative AI-based UiPath Medical Record Summarization agent at Google Cloud Next 2025.